IFNA17 and B-cell non-Hodgkin lymphoma: Phase I clinical evaluation of anti-CD20-IFN-α to treat B-cell lymphomas (ClinicalTrials.gov Identifier NCT02519270) has been initiated and is still ongoing (Table 3).